NxStage reiterated at market outperform by JMP

NxStage Medical, Inc. was rated at market outperform by JMP Securities analyst Robert C. Faulkner. JMP believes the company's successful quarter confirms the strength of the demand drivers and raises its price target to $18 from $13.50. The analyst raised his 2006 revenue forecast to $17.8 million from $16.5 million. Shares of the Lawrence, Mass., medical products company were down 62 cents, or 4.80%, at $12.29 on volume of 34,401 shares versus the three-month running average of 43,807 shares. (Nasdaq: NXTM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.